Biosimilars – Forecast – Overview of Biosimilar Forecasts

In 2022, sales of branded biologics in oncology, immunology, endocrinology, nephrology, respiratory, and ophthalmology exceeded $136 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in these therapy areas totaled approximately $13.3 billion. Throughout the 2022-2032 forecast period, increasing numbers of branded biologics are set to lose patent protection, and biosimilars are expected to enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.

launch Related Market Assessment Reports